Minimal Residual Disease Assessment in Patients with Colorectal Cancer, the MiRDA-C Study

Eligibility Criteria

• 1. Age ≥ 18 years.
• 2. Histological/cytological confirmation of colorectal adenocarcinoma.
• 3. Patients with any stage colorectal adenocarcinoma deemed potentially eligible for curative intent treatment. Patients with stages II-IV colorectal cancer post-R0 resection may also be enrolled onto the protocol any time before or up to 3 months post-surgery and prior to initiating adjuvant therapy.
• 4. Ability to understand and the willingness to sign a written informed consent document.
• 5. Willing to pursue standard of care surveillance post completion of curative therapies.
• 6. Willing to provide blood samples for correlative research.
• 1. Known active malignancies other than colorectal adenocarcinoma that may interfere with detection and / or interpretation of circulating plasma markers. Patients with known clonal hematopoiesis of indeterminate potential are eligible.
• 2. Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.